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Octamethylcyclotetrasiloxane or D4 (CAS
#556-67-2) is a low molecular weight silox-
ane (LMWS) fluid with a low surface ten-
sion, low aqueous solubility, high lipid
solubility, and low vapor pressure (Figure 1,
Table 1). It is present at 40–60% by weight
in personal care products such as antiperspi-
rants, cosmetics, and hair care products
(2–4). Because of its widespread use in these
products, a typical woman is exposed to an
average daily intake (ADI) of 0.158
mg/kg/day (11.1 mg/day) of D4 from daily
use of such products (4). 
D4 is also used to manufacture polydi-
methylsiloxane (PDMS) polymer. PDMS is
commonly used in orthopedic and breast
implants (5). Although breast implants are
composed mostly of stable high molecular
weight siloxanes (HMWS), low molecular
weight siloxanes (LMWS) still exist in the
polymer as impurities (5–9). LMWS consist
of both cyclic and linear molecules with
repeating units of dimethylsiloxane, of
which D4 is a major component (47%)
(7–9). Residual LMWS ranged from 0.2 to
2% by weight for the silicone gel and 0.01%
to 0.1% for the silicone envelope (1.04–10.4
mg) (5–9). Numerous studies have docu-
mented the migration of signiﬁcant amounts
of LMWS out of breast implants into sur-
rounding breast tissues and to the liver
(8–11). This would add to the dermal or
inhalation exposures from personal care
products in a typical woman.
The disposition of [14C]D4 in mice and
rats revealed wide tissue distributions after
intravenous (IV), subcutaneous, and inhala-
tion exposures, respectively (1,12–14).
Female rats exposed to D4 via inhalation
induced more liver metabolizing enzymes
such as cytochrome P450 (CYP) and retained
higher amounts of D4 than did male rats
(1,12,15). CYP is a family of enzymes that
play a major role in the oxidative and reduc-
tive metabolism of many drugs, many xeno-
biotics, and steroids. Two major and three
minor metabolites of D4 have recently been
identified in rat urine (16). At high doses,
mice and rats had enlarged lungs and liver as
well as developmental effects such as
decreased live litter size, number of pups,
and number of uterine implantation sites
(1,4,12,13,15). There is little information
concerning the effects of the highly lipid sol-
uble D4 in humans, but it is not expected to
be inert if it accumulates in the body (9–12).
Previously, Andersen et al. (16) used
physiologically based pharmacokinetic
(PBPK) modeling to determine D4 disposi-
tion in Fisher 344 rats after inhalation doses
(16). Although the model provided a reason-
able simulation of the disposition of D4 dur-
ing exposure, it underestimated the
postexposure levels of D4 experimentally
found in blood and tissues. It failed to
account for the gradual rate of decline of D4
exhalation in rats after exposure, and the
authors reported no extrapolation to human
exposure (16). 
A goal of this study was to develop a vali-
dated PBPK model to relate external
exposure of D4 to internal target dose
(bioavailability) in women with silicone
breast implants. The model was first cali-
brated using previously reported data on tis-
sue distribution in female rats after single
and repeated IV administrations of 14C-D4
(1). We validated the predicted results in
rats and in humans after inhalation expo-
sure using published independent data
(12,17,18). We then used the validated
model to predict the pharmacokinetics of
D4 as leached from saline-filled breast
implants in women.
Methods 
PBPK model. The PBPK model (Figure 2)
uses the actual physicochemical properties of
D4 and physiologic measurements of animals
or humans as a basis for calculating the dispo-
sition of D4. Material balances were written
for D4 for each of the model’s compartments:
lungs, blood, two fat compartments, richly
perfused tissues, gastrointestinal tract, kid-
neys, and liver (see Appendix for details). This
model was based on a previously published
PBPK model for styrene (19) and 4,4´-meth-
ylenedianiline (MDA) (20).
In this model, D4 was metabolized in the
liver, and all the metabolites were excreted in
the urine or feces (1,12). Generally lipids are
transported in blood by various lipoproteins
such as low-density lipoproteins (LDL),
high-density lipoproteins (HDL), and chy-
lomicrons (22). The highly lipid-soluble D4
is likely to be transported in blood by one or
more of these carriers. We found it necessary
for D4 to be bound to two lipoproteins of
different binding affinities (weakly bound
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We developed a physiologically based pharmacokinetic (PBPK) model to predict the target organ
doses of octamethylcyclotetrasiloxane (D4) after intravenous (IV), inhalation, or implantation
exposures. The model used 14C-D4 IV disposition data in rats to estimate tissue distribution coef-
ficients, metabolism, and excretion parameters. We validated the model by comparing the pre-
dicted blood and tissues concentrations of D4 after inhalation to experimental results in both rats
and humans. We then used the model to simulate D4 kinetics after single and/or repeated D4
exposures in rats and humans. The model predicted bioaccumulation of D4 in fatty tissues (e.g.,
breast), especially in women. Because of its high lipid solubility (Log Poct/water = 5.1), D4 persisted
in fat with a half life of 11.1 days after inhalation and 18.2 days after breast implant exposure.
Metabolism and excretion remained constant with repeated exposures, larger doses, and/or differ-
ent routes of exposure. The accumulation of D4 in fatty tissues should play an important role in
the risk assessment of D4 especially in women exposed daily to multiple personal care products
and silicone breast implants. Key words: bioavailability, breast implant, D4, implantation, inhala-
tion, octamethylcyclotetrasiloxane, PBPK, physiologically based pharmacokinetic model, risk
assessment, silicone. Environ Health Perspect 109:1095–1101 (2001). [Online 11 October 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p1095-1101luu/abstract.html
RESEARCH
Articlesand strongly bound) to account for D4
kinetics in blood (1,12). Physiologic values
(e.g., blood ﬂows; tissue and organ volumes)
in the model were taken from the literature
(Table 2). We adjusted other parameters
needed to calibrate the model—such as tissue 
distribution coefficients, metabolism and
excretion parameters, and the blood:air dis-
tribution coefficient (Hair, reciprocal of
Henry’s Law constant)—to fit the experi-
mentally determined tissue distribution
plasma as reported by Kirkpatrick et al. (1).
We solved the equations using an adaptive
grid Runge-Kutta method (Mathcad 8.0;
MathSoft, Inc., Cambridge, MA, USA). The
solutions to these multiple stiff ordinary
differential equations describe the time
course of D4 in the rat. The model predicts
the time course of D4 at target tissues, as well
as excretion rates, and the variation of these
responses as a function of the dose, duration,
and route of exposure. Once we obtained the
best ﬁt for the rat IV experiments, the model
parameters were scaled up to the known
human physiology based on power law (Y = a
M3/4) (23). The model was validated in both
the rat and human by independent predic-
tion and comparison to inhalation results in
both rat and human (12,17).
Model calibration. We calibrated the
PBPK model using blood/tissues distribution
data by Kirkpatrick et al. (1). Briefly, three
groups of 20 Sprague-Dawley (SD) rats (10
males and 10 females) were injected intra-
venously with single 7 mg/kg and 70 mg/kg
and repeated 7 mg/kg daily doses of 14C-D4
for 14 days. Blood samples were taken from
tail vein at predose, 10, 20, 40 min and 1, 2,
4, 6, 12, 24, 36, and 48 hr postdose from
two groups of rats comprising ﬁve animals of
each sex. The animals were subsequently sac-
riﬁced and the liver, kidneys, lungs, and sam-
ples of fat were taken from each animal for
radioactive determination of tissue distribu-
tion of D4. In another group of 10 rats (5
males and 5 females), D4 was administered
intravenously via tail vein at 7 mg/kg 14C-D4
as described above. These animals were
placed in metabolism cages and urine, feces,
and expired air were collected from each ani-
mal 0- to 6-hr, 6- to 12-hr, and subsequent
24-hr intervals for up to 5 days. The animals
were sacrificed at completion and the liver,
kidneys, lungs, samples of fat, gastrointestinal
(GI) tract, and remainder of carcass taken for
measurements of radioactivity.
Model validation. Rat inhalation model.
We extrapolated the rat IV model to simu-
late rat inhalation exposure as reported by
Plotzke et al. (12). In this study, F344 rats
were exposed to 7, 70, or 700 ppm 14C-D4 by
inhalation for 6 hr. Up to 168 hr after expo-
sure, total body burden, excretion in urine,
feces, exhalation, and accumulation in target
tissues (liver, lungs, perirenal fat, ovaries,
vagina, and testes) were measured (12).
Human inhalation model. We scaled
the rat calibrated PBPK model to humans
as described previously, and then compared
the human model prediction for inhalation
exposure with experimental data obtained
from an independent inhalation study (17).
In the human inhalation exposure study,
Utell et al. (17) exposed 12 volunteers
using a mouthpiece-exposure system for 1
hr to either air or 10 ppm (122 µg/L) D4
vapor. Utell et al. (17) divided each expo-
sure into three rest periods of 10, 20, and
10 min, respectively, and two exercise peri-
ods, each of 10-min duration. The order of
D4 exposure was randomized. Exhaled air
samples were collected before, immediately
after exposure, and at 1 and 6 hr after expo-
sure. D4 was extracted from plasma samples
with tetrahydrofuran and the D4 analysis
was performed using gas chromatogra-
phy–mass spectrometry analysis as
described elsewhere (21).
Breast implant exposure. In our simula-
tion, the maximum dose of residual D4 that
could migrate from silicone breast implants
was estimated to be 0.1% wt of the silicone
implant envelope (0.15 mg/kg or 10.4 mg)
(5). The residual D4 was left by incomplete
devolatization of medical polymer (5,7–9). 
Lykissa et al. (9) measured in vitro the
diffusion rate of LMWS (D4-D7) from
explanted silicone gel-filled breast implants
into various surrounding media. The highest
reported diffusion rate (40 µg/g implant/day)
was for a lipid-rich medium such as that
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Figure 1. Three-dimensional structure of D4.
Unique chemical properties were caused by
methyl groups (white), which shield the oxygen
atom (red) and reduced the polarizability of the
molecule.
Table 1. Physical properties of D4.
Property Measures
Molecular weight 296.62
Vapor pressure 1 mm Hg at 25°C
Boiling point 175.4°C
Surface tension 18.796 dynes/cm
Aqueous solubility 56 ppb
Viscosity 2.3 cp at 25°C
Melting point 17.5°C
Log Poctanol:water 5.1
Figure 2. Flow diagram for the PBPK model.
Table 2. Values of physiologic parameters used in the models.
Parameters Rat values Human values
Plasma volume (Vblood) mL 8.5 2,800
Blood ﬂows mL/min
Richly perfused tissues (Qr)4 4 2,054
Fat (Qf) 34.2 442
Liver (Ql) 15.2 1,196
GI tract (Qgi) 11.6 728
Kidney (Qk) 11.7 780
Total cardiac output mL/min (Qt) 116.7 5,200
Lung ventilation rate (Qair) 93.6 mL/min 10–30 L/min
Tissue compartment volumes mL
Lungs (Vlung)1 4 3,800
Richly perfused tissues (Vr) 146 40,672
Fat (Vf) 14.2 14,562
Liver (Vl) 8.0 1,419
GI tract (Vgi) 6.0 948
Kidney (Vk) 1.9 243
See Appendix for nomenclature.
Ventilation gas
IV Dose
Lung
Lipids in blood
Richly perfused
tissue
Deep fat
Fat
Liver
–V max Cliver
GI tract
Feces
Kidney
Urinefound in breast tissue, and the lowest
reported rate was for an aqueous extraction
media (< 1 µg/g implant/day). Given the in
vitro results for D4 into lipid rich medium,
the estimated diffusivity of D4 in the breast
implant shell was 5.4 × 10–8 cm2/sec. Using
published values of the diffusivity for differ-
ent compounds in PDMS and free volume
theory, we also estimated the diffusivity of
D4 to be 2 × 10–8 cm2/sec in the breast
implant shell (24,25). Thus, the leaching
rate of D4 from the shell to the surrounding
fatty tissues of the breasts was estimated to
be 95% removal in 30 days. We obtained
this rate by solving one-dimensional diffu-
sion equation inside a breast implant shell
(5–7 g) exposed to an infinite sink (the
body) using estimated values of the diffusiv-
ity (5.4 × 10–8 cm2/sec, 0.3 mm shell thick-
ness) of D4 (26). This conservative estimate
for diffusion in a rubbery polymer allows for
all of the D4 to be removed from the breast
implant shell rapidly within a month (9). In
the actual human body, external mass trans-
fer resistance will slow the rate down and
allow the D4 to persist in the body even
longer (27). The dose of D4 from silicone
gel implant is expected to be higher (9),
because the initial mass of D4 in the silicone
gel leaching out of the silicone polymer
envelope (which is permeable to its own
components) is higher, even years after
implantation (9–11).
Results
The predicted and experimental plasma and
fat results in the SD rats are shown in Figures
3 and 4, respectively. The model parameters
in the rat are shown in Table 3. The experi-
mental data showed higher accumulation of
radioactivity in female rats than in male rats
at all doses (1,12). We used only the data
from female rats to develop our model
because our goal was to assess the exposure of
D4 in women. 
The plasma radioactivity profiles of
14C-D4 showed nonlinear kinetics for different
dosage regimens (Figure 3). Single IV dose of
7 mg/kg 14C-D4 had two half-lives (t1/2 = 2.1
hr and 12.7 hr) and 14-day repeated daily
dose of 7 mg/kg 14C-D4 had three half-lives
(t1/2 = 3.2 hr, 15.9 hr, and 32.7 hr). Table 4
shows the tissue distribution results obtained
in the IV rat studies. The highest radioactiv-
ity accumulated in fat followed by richly
perfused tissues (i.e., lungs, brain), blood,
liver, and kidneys. Approximately 60–80%
of the absorbed D4 dose was exhaled and
excreted in the urine and feces. Figure 4
shows the predicted and experimental time
and dose response of 14C-D4 in fatty tissues
of the treated rats. 
Table 5 shows the pharmacokinetic
results obtained in the IV rat studies. For the
repeated doses, the exposure as defined by
area under the curve (AUC = 43.4 vs. 663.3
µg hr/mL) substantially increased, but the
clearance remained the same.
To validate the rat model, we compared
the inhalation results obtained from the
model with independent inhalation exposure
data in F344 rats reported by Plotzke at al.
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Figure 3. Predicted and experimental D4 plasma
concentrations in rats exposed by IV.
Figure 4. Predicted and experimental D4 fat con-
centrations in rats exposed by IV.
Table 3. Values of the parameters used in the models.
Parameters Rat values Human values
Deep fat parametersa
Qf2/Qf1 0.059 0.059
Vf2/Vf1 0.73 0.73
D4 distribution coefﬁcientsb
Richly perfused tissue (Dr)1 0 1 0
Weakly bound fat compartment (Df1) 700 700
Strongly bound fat compartment (Df2) 2,000b,c 2,000b,c
Liver (Dl) 7.4d, 160e 7.4
GI tract (Dgi) 0.41 0.41
Kidney (Dk)4 0 4 0
Blood air partition constant, (Hair
a) 20.0 20.0
Kel h–1 f,b 9d, 4e 728
Strongly bound plasma lipoproteinsa
Vstrong mLg 1.0 0.0
Ksi h–1 0.4 –
Kso h–1 0.07 –
Weakly bound plasma lipoproteinsa
Vweak mLg 1.0 10.4
Kwi h–1 0.2 0.2
Kwo h–1 1.0 1.0
Capture efﬁciency, η 0.04e 0.12 resting, 0.07 exercise
Initial inhalation fraction D4 in weakly bound 
plasma lipoprotein, α 0.07e 0.008
Abbreviations: kel, metabolism rate constant, per hour; ksi, forward rate constant for strong protein binding of D4 in
plasma, per hour; kso, reverse rate constant for strong protein binding of D4 in plasma, per hour; kwi, forward rate con-
stant for weak protein binding of D4 in plasma, per hour; kwo, reverse rate constant for weak protein binding of D4 in
plasma, per hour; Qf1, blood ﬂow rate to weakly bound fat compartment, mL/hr; Qf2, blood ﬂow rate to strongly bound fat
compartment; mL/hr. See Appendix for nomenclature.
aBest ﬁt parameters to experimental data. bDetermined from distribution and excretion study in rats (1). cEstimated from
Log P = 5.1. dSprague-Dawley rat. eF344 rat. fScale-up factor (70 kg/0.20 kg), 0.75. gScale-up factor (70 kg/0.20 kg), 0.40. 
Table 4. Comparison of D4 tissue distribution results in rats as a percentage of doses. Experimental values
in parentheses.
Rat IV 14-day
Rat IVa Rat IVa repeated dose
Tissue compartment (7 mg/kg) (70 mg/kg) (7 mg/kg)
Richly perfused tissue 0.83 0.84 0.20
Fat 18.2 (16.3) 18.2 (18.8) 6.9
Liver 0.10 (0.15) 0.10 0.024
GI tract 0.001 0.001 0.0003
Kidneys 0.04 (0.07) 0.04 (0.05) 0.01
Blood 0.15 0.15 0.015
Urine 26.1 (22.3) 26.1  32.2
Feces 8.71 (5.93) 8.71 10.7
Exhaled 42.2 (31.8) 42.2 50.2
aAt the end of 48 hr.
100
10
1
0.1
D
4
 
P
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
i
n
 
S
D
 
r
a
t
s
 
(
µ
g
/
m
L
)
01 02 03 04 05 06 07 0
Time (hr)
7 mg/kg single IV dose
70 mg/kg single IV dose
7 mg/kg IV dose repeated 14 days
Predicted
1,000
100
10
D
4
 
F
a
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
i
n
 
r
a
t
s
 
(
µ
g
/
m
L
)
01 0 2 04 06 0 8 0
Time (hr)
100 120 140
7 mg/kg single IV dose
70 mg/kg single IV dose
7 mg/kg IV dose repeated 14 days
Predicted(12). The F344 rat results were obtained
using higher metabolism rate than in SD rats
(12). Also, the higher ventilation rate in the
rat produced lower capture efﬁciency than in
the human ventilation model. As in the IV
rat model, the experimental inhalation
results in F344 rats also indicated a biphasic
plasma proﬁle as well as slow clearance in fat,
in fairly good agreement with the predic-
tions of the model (Figure 5). These results
showed less accumulation in fat compared
to rat IV exposure results. After 60 hr, the
simulated plasma results were below the
reported experimental data, which were
reported as the limit of detection (0.01
µg/g). Hence, we cannot really compare,
but the model does not conflict with the
experimental results. Previous rat experi-
ments indicated rapid clearance of D4 in
plasma (1).
To validate the human model, we pre-
dicted the absorption, distribution, metabo-
lism, and excretion of D4 after an inhalation
dose and compared it to previously pub-
lished experimental results by Utell et al.
(17). Figure 6 displayed the predicted and
experimental profiles of D4 after a single
dose of 11.1 mg by inhalation for 1 hr in
human plasma and fat, respectively. As
shown, the model was an excellent predictor
of the experimentally determined plasma
concentrations.
Table 6 shows the simulated results for
tissue distribution, exhalation, and excretion
in the urine and feces for human inhalation
and implantation. Table 7 shows the phar-
macokinetics of D4 in plasma. Like fat in
rats, the human fat showed highest accumu-
lation of D4 regardless of dose, regimen, or
route of exposure. 
A single low-dose D4 exposure by inhala-
tion showed fast plasma absorption (Cmax =
69.4 ng/mL at tmax = 1 hr) and fast excretion
[43.8% exhaled, 6.1% in urine, 2% in feces;
Clearance = 407 mL/hr (Table 7)]. Repeated
daily exposure to the same low dose of D4 for
14 days showed higher Cmax value (76
ng/mL) at 145 hr after exposure, increased
area under the curve (AUC = 3,628 ng
hr/mL), increased volume of distribution (Vd
= 1,022 L) and reduced systemic clearance
(Clearance = 357 mL/hr). The implantation
of silicone breast implants had a lower Cmax
of 2 ng/mL compared to a Cmax of 69.4
ng/mL and 76 ng/mL after single or repeated
inhalation of 11.1 mg/day for 7 days, respec-
tively. Comparison of different routes of
exposure in human showed largest volume of
distribution (Vd = 4,100 L) after implanta-
tion, indicating longer retention in the body.
We predicted that D4 systemic exposure
would be longer after implantation (t1/2 = 18
days for D4 in fat) compared to inhalation
(t1/2 = 11 days in fat). The maximum amount
retained in fat for the breast implant case was
174 ng/mL at tmax =11.7 days after implanta-
tion compared to a corresponding Cmax = 330
ng/mL at tmax = 34 hr after inhalation. 
Discussion
Women are prone to bioaccumulate D4
when exposed daily to such multiple per-
sonal care products as antiperspirants, skin
care, or hair care products. A mean dose of
0.158 mg/kg D4 per day by inhalation was
reported in a recent abstract by Shipp et al.
(4). Added to this would be the estimated
dose (10.4 mg/30 days/60 kg = 0.0057
mg/kg/day) of D4 leached from the saline-
ﬁlled silicone breast implants (5–9). For the
first time, the results of the PBPK model
suggest that women accumulate D4 in their
fatty tissues (e.g., breasts), richly perfused tis-
sues, liver, and kidneys. The D4 accumula-
tion increases with the dose, the regimen of
dosing (single vs. repeated), and the routes of
exposure (inhalation vs. implantation). 
The resulting tissue distribution is attrib-
uted to the physical properties of D4, which
is highly lipid soluble and very insoluble in
water (Figure 1, Table 1). Thus, once lipid-
containing tissue (e.g., breast tissue) is
exposed to D4—as occurs when D4 leaches
from breast implants—D4 is rapidly
absorbed and only slowly desorbed with a
very long half-life (fat t1/2 = 18.2 days). D4 is
retained in the body if during exposure it
contacts the lipophilic tissues. Thus neither
inhalation exposure (about a 10% capture of
the intake dose) nor dermal contact (0.5%
absorption) is an efﬁcient way to deliver D4
into internal target organs in the body
(17,28). By contrast, leaching from an
implant directly into breast tissue (mostly
fat) would have great potential for allowing
accumulation of D4 in the body. Repeated
exposures increase accumulation in target tis-
sues since the frequency of exposure is
shorter than the elimination half-life, espe-
cially in certain target tissues.
Fat is the primary tissue depot follow-
ing all routes of exposure, at low and high
doses of D4, with significant longer half-
life than that of plasma (Table 4 and 5). In
the rat, the highest D4 accumulation was
in the fat, followed by richly perfused tis-
sues (e.g., lungs, brain), blood, liver, and
kidneys (Table 4). Single-dose inhalation
results in rats were similar, with rapid
clearance from plasma and a longer half-
life in fat (Figure 5). The single inhalation
route in rats also had poor absorption,
which was consistent with both our inhala-
tion model and published results (12).
Predictions of the PBPK model regarding
plasma, tissue distributions, and excretions
were consistent with the above reported
experimental results (1,12).
In the human inhalation case, the model
predicted that the biphasic plasma half-life
would be 1.7 and 7.4 hr, and the fat half-
life would be 11.1 days. Similarly, the
model predicted that after desorption of D4
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Table 5. Pharmacokinetic results of D4 in rat plasma.
Pharmacokinetic Rat IV – single dose Rat IV – 14 day repeated dose
parameters 7 mg/kg 7 mg/kg
Cmax (µg/mL) 6.7 7.6
tmax (hr) 0 312a
AUC (µg/hr/mL) 43.4 663.2
Cl (mL/hr/kg) 2.42 2.46
Vd (L/kg) 1.05 0.92
t1/2 experimental (hr) 2.1, 12.7 3.2, 15.9, 32.7
t1/2 model (hr) 2.7, 14.0 3.4, 14.4
Abbreviations: AUC, area under the curve of D4 concentration in plasma versus time; Cl, total body clearance; Cmax, maxi-
mum concentration in plasma; tmax, maximum time; t1/2, plasma elimination half-life of D4; Vd, volume of distribution. See
Appendix for nomenclature.
aMaximum concentration occurs immediately after dosing at the beginning of day 14. 
Figure 5. Predicted and experimental D4 plasma
and fat concentrations in rats exposed by inhala-
tion. Limit of detection = 0.01 µg/g.
Figure 6. Predicted and experimental D4 plasma
and fat concentrations in humans exposed by
inhalation.
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Predictedfrom the breast implant in the human, the
plasma half-life would be 7.8 hr and the fat
half-life would be 18.2 days (Table 7). If D4
exposures were repeated in either case at a
frequency shorter than the fat half-life, the
net result would be accumulation in the fat
tissues, because the input would exceed the
elimination output.
These results were not evident from pre-
vious human exposure studies, because the
target tissue disposition was not accurately
determined (17,18). Utell et al. (17) exposed
human volunteers to 129–137 mg D4; the
lungs only captured 10% of D4 exposure by
inhalation (13 mg out of 129–137 mg of
inhaled D4). Thus most of the inhaled dose
(124 mg out of 137 mg) was not absorbed,
which is expected from a combination of
poor gas mixing in the lung, and alveolar tis-
sue mass transfer resistance to hydrophobic
materials such as D4 because of the aqueous
nature of the alveolar membrane. Utell et al.
(17) reported that D4 was rapidly cleared
from plasma, but they did not identify D4
tissues distribution or excretion as predicted
by our model. Our PBPK model did con-
firm the plasma measurements reported by
Utell et al. (17) as well as a nonlinear clear-
ance with two half-lives of 30 min and 330
min and a mean peak value of 79 ng/g
(Table 7 and Figure 6).
The pharmacokinetic results shown in
Tables 5 and 7 for rats and humans, respec-
tively, showed a disproportionate increase
in area under the curve and volume of dis-
tribution at high dose and repeated expo-
sures of D4. The predicted D4 plasma and
fat behavior are similar to that observed with
other volatile lipophilic chemicals such as
styrene (12,20). Because the exposure was
repeated daily, the D4 concentrations in fat
increased, as shown in Table 6. However,
systemic clearance remained about the same
regardless of the route of exposure (Table
7). The shape of the plasma and fat concen-
tration–time curves shown in Figures 3–5
also suggested probable saturation of the
elimination processes. On repeated dosing,
saturation of the elimination processes may
increase the delivered dose of D4 to target
organs such as fat, richly perfused tissues
(e.g., lungs, brain), liver, and kidneys in
both rats (Table 4) and humans (Table 6).
In the liver and kidneys, such accumulation
could produce liver enlargement conﬁrming
experimental results found in mice and rats
(1,13,15). McKim et al. (15) reported some
preliminary results suggesting that repeated
inhalation exposure to high concentrations
of D4 produced liver enlargement with sig-
nificant induction of cytochrome P450
CYP2B1/2 in rats. Analysis of the rat excre-
tion results (Table 4) showed no compelling
evidence of D4 CYP enzyme induction.
Furthermore, there is a more reliable way
(e.g., using yeast that contains human
genes) to determine whether D4 chemically
induced P450 in humans.
The model predicted 43% and 53% of
the dose of D4 in exhaled air after single and
repeated inhalation exposures, respectively.
Similarly, 59% of D4 was exhaled in air after
breast implantation (Table 6). The model
results were comparable with the exhalation
data reported by others (1,3,12,15,17). The
PBPK model used the blood:air partition
coefﬁcient to estimate the exhalation data of
D4. The blood:air partition coefficient that
best ﬁt the experimental data [shown in Table
3 as Hair (20.0)], was not consistent with the
water:air partition coefﬁcient values for D4.
The published Henry’s law constants for D4
(air:water) have been reported in the range of
3–32, which is equivalent to water:air parti-
tion coefﬁcient of 0.33 to 0.031 (27,29–32).
The discrepancy was attributed to both the
low solubility of D4 in water (56 ppb) and its
binding to blood lipoproteins, which
increased the value of the blood:air partition
coefficient relative to its corresponding
water:air partition coefﬁcient (33). Beliveau
and Krishnan (33) indicated that the
blood:air partition coefficients of lipophilic
volatile organic compounds (e.g., D4, styrene)
could not be determined using water:air
partition coefficients. They published a
methodology to account for this solubility
enhancement of protein binding for estimat-
ing the blood:air partition coefﬁcients using
oil:water and n-octanol:hemoglobin:water
mixtures instead of a simple water:air mea-
surements (33). The high lipid afﬁnity of D4
for blood proteins makes this effect even more
signiﬁcant for this case. We suspected that a
smaller blood:air partition coefﬁcient (< 20)
was used in a reported model by Anderson et
al. (16). This could have led the authors to
underestimate the postexposure blood and tis-
sues levels of D4 in rat (16).
We developed a PBPK model to deter-
mine the time course of D4 in the human
body after exposure at different doses and
routes in rats and humans. The simulation
results suggest that D4’s unique physico-
chemical properties play an important role
in the bioavailability of this chemical. It is
absorbed rapidly and retained in the fatty
tissues for a longer time when it contacts
lipophilic tissues directly (e.g., breast
implants). The repeated daily inhalation
exposures to D4 would accumulate this
compound in fat, liver, and kidneys signiﬁ-
cantly to saturate its elimination processes.
This accumulation is likely to occur in
women because physiologically women have
a large volume of adipose tissues and a
slower metabolism than do men. Future
studies are expected to extend our toxicoki-
netic evaluation of D4 such that we could
accurately assess the safety of D4 based on
its bioavailability and target doses, not by
consideration of the dose level alone.
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Table 6. Comparison of D4 tissue distribution results in rats and humans as a percentage of doses. Rat
experimental values in parentheses.
Human inhalation Human inhalation Human breast
Tissue Rat IVa single exposureb exposure, repeatedc implant exposure
compartment (7 mg/kg) (11.1 mg) (77.7 mg) (10.4 mg)d
Richly perfused tissue 0.83 7.9 2.2 1.7
Fat 18.2 (16.3) 39.7 35.0 27.6
Liver 0.10 (0.15) 0.14 0.04 0.04
GI tract 0.001 0.005 0.001 0.002
Kidneys 0.04 (0.07) 0.14 0.04 0.04
Blood 0.15 0.08 0.01 0.01
Urine 26.1 (22.3) 6.1 7.3 8.6
Feces 8.71 (5.93) 2.0 2.4 2.9
Exhaled 42.2 (31.8) 43.8 53.1 59.1
aAt the end of 48 hr. bAt the end of 24 hr. cAt the end of 7 days. dAt the end of 7 days.
Table 7. Pharmacokinetic results of D4 in human plasma.
Human inhalation Human breast
Human inhalation exposure, 7-day implant
Pharmacokinetic exposure repeated dose exposurea
parameters (11.1 mg) (77.7 mg) (10.4 mg)
Cmax (ng/mL) 69.4 76.0 2.0
tmax (hr) 1 145 35
AUC (ng/hr/mL) 453.4 3,628 427.8
Cl (mL/hr) 407 357 329
Vd (L) 159.8 1,022 4,100
t1/2 (hr) 1.7, 7.4b 1.1, 8.5b 7.8 
Abbreviations: AUC, area under the curve of D4 concentration in plasma versus time; Clearance (Cl), total body clear-
ance; Cmax, maximum concentration in plasma; tmax, maximum time; t1/2, the elimination half life of D4 in plasma; Vd , vol-
ume of distribution.
a81.4% of this dose of D4 desorbed into the body at the end of 14 days. bBiphasic half-life. Articles • Luu and Hutter
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Appendix
The material balances for both D4 and its metabolites for the model
shown in Figure 2 were solved using MathCad 8.0 (MathSoft, Inc.,
Cambridge, MA, USA). We used an adaptive grid Runge-Kutta
method for the system of stiff ordinary differential equations. We cal-
ibrated the rat model using an IV dose; this was introduced as a forc-
ing function partitioned to all of the compartments in the model. In
that way, the D4 was distributed to all compartments in the body,
allowing the numerical procedure to converge to a solution. In the
human inhalation or breast implant case, the D4 was introduced
directly to the lung or into the systemic circulation at the mix point,
similar to previous models (12,13). A nomenclature list is included at
the end of this appendix. The following equations are the material
balances for D4:
For the lung, 
For the richly perfused tissues, 
For the deep fat compartment, 
For the weakly bound fat compartment,
For the liver,
For the GI tract, 
For the kidneys,
We determined the total metabolites generated by integrating the
accumulation equation below,
In the blood, D4 exists dissolved in the plasma (aqueous), weakly
bound to protein, and strongly bound to protein. The venous blood
is well mixed before it is returned to the arterial circulation. At this
mix point, the D4 protein binding is calculated. For D4 in the
plasma,
For the weakly bound D4 in the blood,
For the strongly bound D4 in the blood,
For the IV case in the rat, we solved the above equations with the
initial conditions that all the compartments except the weakly bound
D4 in the blood have zero concentration at t = 0. The weakly bound
D4 in the blood was assigned an initial concentration of D4 equal to
5% of the IV dose at t = 0; this was a better ﬁt of the experimental data.
For the rat, the IV dose was input using the following forcing
function.
For the human, the IV dose was replaced by either an inhalation
dose or implant dose. Using the data of Utell et al. (11), we exposed
subjects to 10 ppm D4 by inhalation for 1 hr. This exposure period
consisted of 10 min rest, 10 min exercise, 20 min rest, 10 min exer-
cise, and ﬁnally 10 min rest before the D4 inhalation was terminated.
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Appendix 1, Table 1. Nomenclature.
Cai Concentration of D4 dissolved in plasma, mol/mL
Cair Concentration of D4 in inhalation air, mol/L
Cf1 Concentration of D4 in weakly bound fat compartment, mol/mL
Cf2 Concentration of D4 in strongly bound fat compartment, mol/mL
Cgi Concentration of D4 in GI tract, mol/mL
Ck Concentration of D4 in kidneys, mol/mL
Cinj Concentration of D4 in IV ﬂuid, mol/mL
Cr Concentration of D4 in richly perfused tissue, mol/mL
Cwk Concentration of D4 weakly protein bound in plasma, mol/mL
Cstr Concentration of D4 strongly protein bound in plasma, mol/mL
D0 Available dose of D4 in breast implant shell, mol
Df1 Distribution coefﬁcient of D4 in weakly bound fat compartment, 
dimensionless
Df2 Distribution coefﬁcient of D4 in strongly bound fat compartment, 
dimensionless
Dgi Distribution coefﬁcient of D4 in GI tract, dimensionless
Dk Distribution coefﬁcient of D4 in kidney, dimensionless
Dl Distribution coefﬁcient of D4 in liver, dimensionless
Dr Distribution coefﬁcient of D4 in richly perfused tissue, dimensionless
Hair Blood:air partition constant of D4 in plasma, dimensionless
kba Desorption constant of D4 from breast implant shell, h–1
ksi Forward rate constant for strong protein binding of D4 in plasma, h–1
kel Metabolism rate constant, h–1
kso Reverse rate constant for strong protein binding of D4 in plasma, h–1
kwi Forward rate constant for weak protein binding of D4 in plasma, h–1
kwo Reverse rate constant for weak protein binding of D4 in plasma, h–1 
Qair Lung ventilation rate, L/hr
Qexercise Lung ventilation rate during exercise, L/hr
Qrest Lung ventilation rate during rest, L/hr
Qf1 Blood ﬂow rate to weakly bound fat compartment, mL/hr
Qf2 Blood ﬂow rate to strongly bound fat compartment, mL/hr
Qgi Blood ﬂow rate to GI tract, mL/hr
Qinj Flow rate of IV, mL/hr
Qk Blood ﬂow rate to kidneys, mL/hr
Ql Blood ﬂow rate to liver, mL/hr
Qr Blood ﬂow rate to richly perfused tissues, mL/hr
Qt Total cardiac output, mL/hr
t Time, hr
tinj Duration of IV, hr
Vblood Plasma volume, mL
Vf1 Volume of weakly bound fat compartment, mL
Vf2 Volume of strongly bound fat compartment, mL
Vgi Volume of GI tract, mL
Vk Volume of kidneys, mL
Vl Volume of liver, mL
Vlung Volume of lungs, mL
Vr Volume of richly perfused tissue, mL
Vstrong Volume of strongly bound plasma, mL
Vweak Volume of weakly bound plasma, mLREFERENCES AND NOTES
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To model this, we deﬁned ﬁve forcing functions covering each period
of exposure. The inhalation rate was set at 10 L/min during rest, and
30 L/min during exercise. Using Utell et al.’s (11) published capture
efﬁciencies of the human lung of 0.12 during rest and 0.07 during
exercise, we delivered a total dose of 11.1 mg of D4 to the human
body during the exposure. The following equations were used,
During the exposure, Qair in equation 1 is also stepped between
Qrest and Qexercise during the 1-hr exposure. After exposure, the lung
ventilation rate was set to the resting value. In the human case, unlike
the rat, all of the compartments contained no D4 at t = 0. Also,
unlike the rat where 5% of the D4 was initially bound to the blood
plasma, in the human this value was set to 0.8% of the dose delivered
by the functions
.
For the human breast implant exposure, the inhalation forcing
functions were replaced by a ﬁrst-order desorption.
 kD exp –k t ba 0 ba ()
   χχ 15 t – t () ()
   χ5 50 60 0 tt Q C rest in ()=≤ < () if min, ,
   χ4 40 50 0 tt Q C exercise in ()=≤ < () if min, ,
   χ3 20 40 0 tt Q C rest in ()=≤ < () if min, ,
χ2 10 20 0 tt Q C exercise in ()=≤ < () if min, ,
   χ1 rest in tt Q C ()=< () if 10 0 min, ,1102 VOLUME 109 | NUMBER 11 | November 2001 • Environmental Health Perspectives